Neurogene (NGNE) EBT Margin (2018 - 2024)
Neurogene's (NGNE) quarterly EBT Margin came in at 3416.11% in Q2 2024, down 57059.96% on a QoQ basis from 5.98% in Q3 2019.
Neurogene (NGNE) EBT Margin (2018 - 2024) Analysis & Trends
Neurogene (NGNE) has 3 years of EBT Margin data on file, last reported at 3416.11% in Q2 2024.
- Quarterly EBT Margin changed N/A year-over-year to 3416.11% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 11637.62% (up 12476.0% YoY) and the FY2024 annual result came in at 20444.32%, changed N/A from the prior year.
- EBT Margin retreated to 3416.11% in Q2 2024, from 5.98% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 3416.11% in Q2 2024 to a low of 3416.11% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -3,416.11% |
| Sep 30, 2019 | -5.98% |
| Jun 30, 2018 | 10.85% |